Target plasma concentrations determined in preclinical studies could be safely achieved in a Phase I study. At these plasma concentrations, CNS target engagement was confirmed in healthy volunteers. This approach has supported the design of the current Phase 2 clinical trial in Friedreich´s Ataxia, and also in other indications.
Wednesday, September 8, 2021
A translational approach to determine target concentrations of MIN-102 (leriglitazone) to support a Phase II study in Friedreich’s ataxia
S. Poli, L. Rodríguez-Pascau, J. Ros, P. González-Cabo, E. Britti, D. Lynch, G. Pina, S. Pascual, M. Cerrada-Gimenez, D. Eckland, E. Traver, J. Wetering-de-Rooij, M. Martinell, U. Meya, P. Pizcueta.; Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/a-translational-approach-to-determine-target-concentrations-of-min-102-leriglitazone-to-support-a-phase-ii-study-in-friedreichs-ataxia/. Accessed September 7, 2021.
